NeuroSense faces Nasdaq delisting risk after missing $35 million market value rule

• NeuroSense received a Nasdaq staff delisting determination for failing to meet the $35 million minimum market value of listed securities rule.
• Noncompliance with Listing Rule 5550(b)(2) persisted through the Sept. 29 deadline following a 180-day cure period that began April 2.
• Ordinary shares and warrants face delisting unless a Nasdaq Hearings Panel appeal is filed; a timely request stays suspension pending a decision.
• Compliance with the $1.00 minimum bid price rule was regained following a 1-for-20 reverse split, closing that deficiency.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurosense Therapeutics Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610021615PR_NEWS_USPR_____LN62692) on October 02, 2026, and is solely responsible for the information contained therein.